Tempus is a data analytics company that was founded by Eric Lefkofsky. The company has software and computers that can store, process and sift through large amounts of data to find patterns. Recently, Tempus has begun a partnership with the University of Chicago to help better treat cases of breast cancer.
Tempus’ capabilities include being able to do genomic sequencing for patients who are receiving treatment at the University of Chicago for breast cancer. In addition the company utilizes machine learning technology to build upon previous data from both past and existing patients. Genomic sequencing when combined with machine learning give cancer researchers and physicians a vast swathe of data that can better predict how a person will respond to a certain treatment option for cancer and how likely that treatment will be successful.
Doctors at the University of Chicago say that there is a large amount of information out there on cancer patients. They also say that there is lack of storage, analysis and sharing of data when it comes to past cancer patients. Tempus is changing this by storing data and allowing it to be shared and analyzed. The hope is that Tempus can help customize medicine and create an effective individually customized cancer solution for every patient that will be most effective for them.
Eric Lefkofsky is also the founder of Groupon. This is a popular online marketing company. Its business model involves working with businesses to offer customers large discounts or sales on products and services. In exchange for offering these large discounts or sales, the business or corporation is given access to a large customer base that is willing to try out the new product or service at the discounted value. Businesses get access to a large customer base, while customers get discounts and special offers through Groupon.
Mr. Lefkofsky also has an investment venture that is called Lightbank. This venture invests money in startups that have the potential to impact society or develop into big companies. Both Lightbank, Tempus and Groupon are based in the windy city of Chicago at 600 West Chicago Avenue along the banks of the Chicago River.
Eric Lefkofsky is the founder of Tempus, a cancer-fighting startup that aims to provide accurate data to the doctors serving at the University of Chicago so as to aid in treating breast cancer patients. Tempus, Chicago-based institution, has partnered with the University of Chicago Medicine so as to provide the University doctors and students with molecular sequencing and analysis to breast cancer specialists. This will help them create treatment plans regarding each person’s needs. The primary objective of Tempus is to provide data that lead to better results and permanent outcomes.
Eric Lefkofsky is an American Entrepreneur, co-founder and the Chief Executive Officer of the Tempus. Mr Eric has co-founded other organizations such as Groupon, where he is also a chairman, Echo Global Logistics, Mediaocean, Uptake, and the InnerWorkings. Eric Lefkofsky grew up and studied in Southfield, Michigan alongside his two siblings. He is the son of Bill and Sandy, an engineer and school teacher respectively. Eric has two siblings, one brother, and a sister, and they are all Jewish. Erick Paul attended Southfield-Lathrup High School and later joined the University of Michigan where he graduated with Honors.
Eric Lefkofsky has been an entrepreneur since he left college. His entrepreneurial journey started when he and his friend bought a company with capital borrowed from family and relatives. He later created an internet company that used to promote products online. He once served as the Chief Operating Officer of Halo till it got resolved in 2004. He created a logistics company, a media-technology company, which later turned to be a media Bank. He has served in these ventures as a co-founder and Chairman of the Board and the Chief Executive Officer for some. In 2016, he founded Tempus, which is expected to be of much help to the Chicago breast cancer patients. Click here to know more.
Cancer Treatment Centers of America is one of the country’s foremost centers for the treatment of cancer. Using cutting-edge treatments and some of the America’s most talented physicians and oncologists, Cancer Treatment Centers of America has helped thousands of Americans beat cancer and return to fulfilling lives.
Recently, Cancer Treatment Centers of America has implemented a new software program designed to streamline the process of fighting cancer and selecting the appropriate treatment. Its physicians now have at their disposal one of the most advanced and accurate diagnostic systems available today in the cancer treatment field.
The system, named Clinical Pathways, draws from an immense database of evidence-based treatments and clinical information. The system can help oncologists in selecting the most appropriate course for the patient-specific disease characteristics that presents before them. Clinical Pathways has a database of over 2,700 detailed and extensive clinical summaries of treatment programs, drug information and holistic considerations that help the patient get through their specific course of treatment in the highest level of comfort possible.
It is anticipated that clinical diagnostic systems like Clinical Pathways will revolutionize the treatment of cancer, freeing up both patients and physicians to concentrate on more important tasks than worrying about medical minutiae.
According to Wikipedia, the system also eliminates the possibility of making clerical errors that can often times lead to the wrong drugs being prescribed and overdose or deadly adverse drug reactions in some patients. The system will also be used as a way to show patients, and simple to understand terms, the likely clinical course of their disease and the possible spectrum of outcomes that they can expect from their treatment.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America is the country’s largest network of private cancer treatment facilities. More information suggestions are at https://www.myctca.com/. With five branches throughout the United States, it has helped thousands of people overcome the potentially deadly disease and return to a normal and fulfilling life, remaining cancer free.
For more information follow CTCA follow them on Facebook.
Cancer Treatment Centers of America has partnered with All Scripts and NantHealth in order to provide even better cancer care treatment than ever before. CTCA and its new partners are going to create Clinical Pathways. Clinical Pathways supplies the physician with information about cutting-edge cancer treatment, proving the physician with unlimited options for treatment by eliminating any guesswork.
Cancer Treatment Centers of America was founded in 1988 in Schaumburg, Illinois by Richard J Stephenson who was dissatisfied with the cancer treatment his mother received prior to her death. He created this innovative cancer treatment so others in need of cancer treatment, get better care than Mrs. Stephenson did. Between 2005 and 2012, for CTCA hospitals were opened In addition to Zion, Illinois, there are treatment centers in Philadelphia, PA, Goodyear, AZ, Tulsa, Oklahoma, and Newman, Georgia. Two yeas ago, the headquarters of CTCA was moved to Boca Raton, Florida. It’s now known as Cancer Treatment Center of America Global.
Cancer Treatment Center of America is unique because the staff believes that every person with cancer is an individual. It is not just here’s the chemo and the radiation treatment. Cancer Treatment of America can use chemotherapy, but the staff also believes in putting patients on a special diet and creating an individual treatment plan. What might work for some patients may not work well for others.
According to Wikipedia, Cancer Treatment of America has better results than the country’s average. Breast Cancer patients thrive at 20 percent higher results than the country average. Five years after diagnosis prostate cancer averages seven points higher than average. After one year after diagnosis, prostate cancer patients average around 16 points higher success than the national average. In fact, most recently, CTCA is working with immunotherapy to help cancer patients be able to stop chemo treatments.
Dr. Clay Siegall, the founder, Chief Executive Officer, President and Chairman of the Board of Seattle Genetics brings a wealth of experience to this industry. He has a Ph.D. in Genetics from George Washington University. Previously, He worked at the National Cancer Institute and the National Health Institute between 1988 and 1991. He then went on to Bristol-Myers Squibb Pharmaceutical Research Institute, where he worked from 1991-1997. When Bristol-Myers decided to close its operations in Seattle, he went on to form Seattle Genetics based on the passion he had for making cancer treatment available and affordable to all.
It is during Dr. Siegall’s tenure at Seattle Genetics that the company has built a portfolio of antibody-based cancer therapies. The most well known of these is ADCETRIS (brentuximab vedotin), was granted approval by the United States Food and Drug Administration in 2001. This drug is currently available in 65 countries. Clay Siegall has also been instrumental in fundraising activities, having secured over $330 million through private and public financing. He has also secured strategic ADC collaborations with other companies like Genentech, Bayer, and Progenics among others, which have generated at least $65 million since 2001.
Dr. Clay Siegall’s dedication to the treatment and possible cure of cancer and other life-threatening illnesses using ADC therapy is a challenge to all of us. He has made this his life’s purpose. He has written over 70 publications and holds over 15 patents, all of which prove that he has a lot more in store for the medical world. Clay Siegall’s expertise in this field has led to his being invited to sit on the Boards of other companies, including Alder Biopharmaceuticals, Mirna Therapeutics, and Ultragenyx. Based on what he has achieved so far at Seattle Genetics, it is clear that Dr. Siegall is a man to watch in the field of genetics and ADC therapy.